Patents by Inventor Maier Lorizate Nogales

Maier Lorizate Nogales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-proteolysable oligopeptides that inhibit glycoprotein GP41 of the aids virus
    Patent number: 8110545
    Abstract: The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhibit the binding of a retrovirus to a target cell, thereby providing novel therapies against infection from the human immunodeficiency virus (HIV). The invention also relates to the use of said D-hexapeptides in the form of single components or complex mixtures as prophylactic or therapeutic agents for retroviral infections, especially human immunodeficiency virus type 1 (HIV-1).
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: February 7, 2012
    Assignees: Universidad Del Pais Vasco, Universidad de Valencia
    Inventors: Jose Luis Nieva Escandon, Maria Jose Gomara Elena, Maier Lorizate Nogales, Nerea Huarte Arrayago, Ismael Mingarro Munoz, Enrique Perez Paya
  • NON-PROTEOLYSABLE OLIGOPEPTIDES THAT INHIBIT GLYCOPROTEIN GP41 OF THE AIDS VIRUS
    Publication number: 20100197606
    Abstract: The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhibit the binding of a retrovirus to a target cell, thereby providing novel therapies against infection from the human immunodeficiency virus (HIV). The invention also relates to the use of said D-hexapeptides in the form of single components or complex mixtures as prophylactic or therapeutic agents for retroviral infections, especially human immunodeficiency virus type 1 (HIV-1).
    Type: Application
    Filed: December 29, 2006
    Publication date: August 5, 2010
    Inventors: José Luis Nieva Escandón, Maria José Gómara Elena, Maier Lorizate Nogales, Nerea Huarte Arrayago, Ismael Mingarro Munoz, Enrique Pérez Paya